Opiate Substitution Treatment and Harm Reduction in prisons: the Geneva model PD Dr Hans Wolff University Hospitals Geneva

Slides:



Advertisements
Similar presentations
Children and young people, injecting and HIV Under-18 and overlooked Young People and Injecting Drug Use: Overcoming barriers to HIV Prevention and Harmonizing.
Advertisements

Workshop IV: Provision of Health Care The Impact of International Standards and Guidelines on prisoner health in Eastern and Central Europe Antalya, Turkey.
No one left behind: Increased coverage, better programmes and maximum impact for key populations WHO Consolidated Guidelines on HIV Prevention, Diagnosis,
Turning the tide: Not without prisons! Promoting comprehensive national HIV responses.
Needle and syringe programmes in prisons
The U.S. President’s Emergency Plan for AIDS Relief The Evolving HIV Prevention Strategy for IDUs in PEPFAR Amb. Eric Goosby US Global AIDS Coordinator.
2 emcdda.europa.eu European drug report package A comprehensive analysis on the drugs problem in Europe.
Bringing Opioid Substitution Treatment to scale Dr. M. Suresh Kumar Inter-country Consultation on Preventing HIV among IDUs Scaling Up: From Evidence to.
The Global Burden of Hepatitis C Dr Daniel Lavanchy World Health Organization (WHO) Geneva, Switzerland 3 rd Paris Hepatitis Conference.
Washington D.C., USA, July 2012www.aids2012.org Working together for the implementation of prevention, medical care and harm reduction in prisons:
In prison drugs do not enter! that's what the authorities mostly say… Daniela De Santis Prevention coordinator Switzerland January 2014.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
GAP Report 2014 Prisoners People left behind: Prisoners Link with the pdf, Prisoners.
A Call for Action HIV/AIDS & Hepatitis C in Irish Prisons Irish Penal Reform Trust & Merchants Quay Ireland by Rick Lines, MA July 26, 2002.
Harm Reduction and Drug Policy in Western European Prisons “HIV, Hepatitis C, and Harm Reduction in prisons: Evidence, Best Practice and Human Rights“
“Humanitarian Action” The Saint-Petersburg Charitable Foundation for Medical and Social Programs HAF.
Operational Approaches for Comprehensive Sex Worker Programmes An overview of Implementing Comprehensive HIV/STI Programmes with Sex Workers: Practical.
Slide 5.1 Topic 5. Supporting programs aimed at reducing the spread of HIV among and from IDU Needle and Syringe Programs Opioid Substitution Treatment.
HIV Prevention, treatment and care among people who inject drugs Fabienne Hariga, MD, MPH Senior HIV Adviser, UNODC Vienna.
Annabel Baddeley Global TB Programme WHO, Geneva
+ Opioid Substitution Therapy for Injecting Drug Users: Scale versus Quality WORKSHOP “OST in Developing Countries: A Primer” Atul Ambekar, Alok Agrawal.
Drug use, related problems and interventions targeting drug users in prison in the European countries: main issues and challenges for the future Linda.
Afghanistan’s Present IDUs-HIV/AIDS Situation and future action plan Dr.Saifur-Rehman NACP Director April,11,2007 Islamic Republic of Afghanistan Ministry.
HIV AIDS Section Fabienne Hariga Senior Adviser UNODC HIV AIDS section, Vienna Comprehensive package of interventions for HIV in prison settings AIDS 2012.
The UK Drugs Situation: Data, information and uses Charlotte Davies, UK Focal Point Project Manager 1.
 Insufficient Reliable data in this region  Estimated people living with HIV  The number of new HIV infections in the region increased.
HIV/AIDS in Prison Settings Dr. Monica Beg HIV/AIDS Unit, United Nations Office on Drugs and Crime, Krakow, Poland September 27, 2004.
Guidance on Provider-initiated Voluntary Medical Examination, Testing and Counselling for Infectious Diseases in Injecting Drug Users Hans Blystad 1 and.
Treatment of drug addiction in prisons
Harm Reduction.
At the frontier of drug harm reduction Prisoners’ rights to health & safety David McDonald Visiting Fellow National Centre for Epidemiology and Population.
HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania Signe ROTBERGA UNODC, Baltic States 5 November.
Recommendations on the Management of Opioid Overdose Ruth Birgin.
Results from the Spanish experience: A comprehensive approach to HIV and HCV in prisons MERCEDES GALLIZO LLAMAS Secretary-General of Spanish Prison Administration.
HARM REDUCTION RESPONSES TO DRUGS IN THE EUROPEAN UNION – FROM MARGIN TO MAINSTREAM 8 th Annual Meeting of the European Red Cross / Red Crescent Network.
Annual report 2010: the state of the drugs problem in Europe.
Medical Professionalism and its Relationship to Public Health: Physician Advocacy and State Public Health Policy Thomas Kellogg Program Officer and Advisor.
An overview of European trends and developments Roland Simon ECAD Meeting 2011, Varna.
If I ruled the world… Presentation to Prisons and Beyond NOMS Prison Drug Strategy Unit, in association with the Federation of Drug & Alcohol Professionals.
Theodore M. Hammett, Ph.D. Sofia Kennedy, M.P.H. Drug Abuse and Risky Behaviors: The Evolving Dynamics of HIV/AIDS NIH-Bethesda, MD May 9, 2007 HIV/AIDS.
A global perspective on scaling up harm reduction 2 nd National Harm Reduction Conference, Ukraine, March 2007 Dr Jos Perriens, Director Prevention.
June 14, 2013 Harm Reduction and Drug Policy Reform 1 Harm Reduction and Drug Policy Reform in the U. S. Laura Thomas, MPH, MPP Drug Policy Alliance MIDARP's.
MRCPsych addiction psychiatry seminar series Policy, guidance, service structures and legal framework of addiction treatment Epidemiology of addictive.
Clinical Management of Substance Misuse Dave Marteau Prison Health
Ester Wina 24 July th IAC, Melbourne, Australia.
Harm Reduction International
School of Public Health and Community Medicine How policies and repressive law- enforcement fuel the HIV epidemic among people who inject drugs Professor.
BEST PRACTICE PORTAL BEST PRACTICE PORTAL project presentation to the Scientific Committee Ferri et al Lisbon, 16th July 2010.
HIV Prevention, Treatment and Care in Prisons and other Closed Settings Ehab Salah Prisons and HIV Advisor UNODC, Vienna ICASA 2015 Harare, Zimbabwe 2.
Understanding Drug Abuse and Addiction: What Science Says Developed by the National Institute on Drug Abuse (NIDA) National Institutes of Health Bethesda,
Effective HIV & SRH Responses among Key Populations Module 2: The Comprehensive Package of Programmes and Services.
19 June 2007 Prison & Health Expert Meeting Paris Drugs and prisons DG SANCO C4 N. GRENIER.
From evidence to commitment to action: implementing HIV prevention measures in prisons in Ukraine XVI International AIDS Conference Toronto, 15 August.
Skills Building Workshop – Conducting Situation and Needs Assessments in Prison Settings HIV and AIDS in Prisons Overview of Issues and Challenges Brian.
Health in Prisons Project Oslo, 24 November 2009 Lars Moller Regional Adviser a.i. World Health Organization Regional Office for Europe Health in Prisons.
Rauni Ruohonen FILHA Priorities of TB control in penitentiary care.
Harm reduction evidence: Eastern Europe and Central Asia Raminta Stuikyte Central and Eastern European Harm Reduction Network.
TB AND HIV: “THE STRATEGIC VISION FOR THE COUNTRY” Dr Lindiwe Mvusi 18 May 2012 MMPA Congress 2012.
Universal Access Charter The Universal Access Charter is intended to be the voice of communities and civil societies around the world; The Charter is a.
Presented by Nathalie Rose Social Worker PILS (Prevention Information Lutte contre le Sida) 5 August, 2008 IAC.
MODULE 3 Harm reduction advocacy
Dr. Monica Beg, Chief, HIV/AIDS Section, UNODC
Cascade of care for people who use drugs - opportunities for integration and scale up of harm reduction services and other evidence based interventions.
Fabienne Hariga Senior Adviser, HIV/AIDS Section
Evidence for Action: Effectiveness of HIV/AIDS interventions in prison settings In 2005, WHO commissioned a review of the evidence of the effectiveness.
Addressing Drug Use Together Through a Health Based Approach:
WHO minimum public health data set on prison health
Health Care for Drug Users in Prisons Prof. Dr. Heino Stöver, Prof. Dr
National Programme for limiting spread of HIV/AIDS in Latvia 2008–2012
Towards a Conducive Legal and Structural Environment
Presentation transcript:

Opiate Substitution Treatment and Harm Reduction in prisons: the Geneva model PD Dr Hans Wolff University Hospitals Geneva

Plan Prisons in Switzerland Switzerland: Examples of realizations at the prison medicine unit in Geneva Opiate substitution treatment (OST) and harm reduction in prison Needle and syringe exchange

3 Language regions & bordering countries Switzerland

4 1 country – 26 cantons Switzerland

Incarceration in Switzerland General Population: 7 Mio 113 Prisons: 6065 detainees in 2011 – 78 detainees/100’000 inhabitants World (2008): 10.1 Mio detainees: ¼ in the US (2.3 Mio, 9 Mio/year ), ¼ in Russia and China USA (costs) $49 Billion/year, 70’000,-$/inmate/year

1.Information, education and communication 2.HIV testing and counselling 3.Treatment, care and support 4.Prevention, diagnosis and treatment of tuberculosis 5.Prevention of mother-to-child transmission of HIV 6.Condom programmes 7.Prevention and treatment of sexually transmitted infections 8.Prevention of sexual violence 9.Drug dependence treatment including Opioid Substitution Therapy 10.Needle and syringe programmes 11.Vaccination, diagnosis and treatment of viral hepatitis 12.Post-exposure prophylaxis 13.Prevention of transmission through medical or dental services 14.Prevention of transmission through tattooing, piercing and other forms of skin penetration 15.Protecting staff from occupational hazards Prevention in Prison The Comprehensive Package (UNOCD): 15 Key interventions

Reduce or stop illegal drug use Improve physical, mental and social well-being of the patient Prevent and reduce infectious diseases, including HIV and hepatitis Reduce mortality, in particular through overdose Reduce morbidity Improve the quality of life of the patient and his family Reduce public spending in health care Reduce public spending in the criminal justice system Opiate Substitution Treatment (OST) delivered appropriately will: Guidelines Euromethwork

Reduce mortality by overdose Carrieri & al 2006 n

I Sheerin & al. Reduction in crime by drug users on a methadone maintenance therapy in New Zealand. The New Zealand medical Journal; 12 March 2004 vol117, n°1190 ISSN Reduction of criminality Number of days with criminal act per week Two interviews (85 patients ) First interview before MMT (methadone maintenance treatment) The second, after a mean MMT of 57 months p<0,001 n

Cost-effective 1 $ invested in OST, Saves 38 $ (cost related to criminal activity, further incarcerations, unemployment, hospitalizations, medical follow-up) $1 $38 MMT CostSavings Gary A. Zarkin, Laura J. Dunlap, Katherine A. Hicks and Daniel Mamo Additional contact information Health Economics, 2005, vol. 14, issue 11, p

Harm Reduction International, The global state of harm reduction 2012 Access to OST in the community and in prison

Time gaps in the official introduction of OST in prisons: ~7-8y (Source: EMCDDA, Statistical Bulletin 2011, HSR tables) Thanks to H. Stöver

Opioid users in Geneva’s prison Epidemiology Prevalence: 8% Male : 95,3% Mean age : 29,7 Previous incarceration : 74,7 % Intravenous users : 39,9 % Used other substances (legal or illegal) : 94,8% – Cocaine :70,8% – Tranquilizers : 63,5% – Alcohol :55,4% – Canabis : 44,2%

Opiate substitution therapy (OST) in the prison of Champ-Dollon (Geneva) Start 1970 (formal authorization in 1996) Pragmatic approach Politics of 4 pillars (Prevention, Harm reduction, treatment, repression) MTD/Buprenorphine: – start or continue treatment – 5-10% with OST – 100% of those who wish or need substitution receive OST 0 overdose the last 10 years 14

Injecting & Syringe Sharing in Prison LocationN% injected% sharedReference Australia (NSW) 7 studies Potter 1989; Wodak 1989; Dolan 1996,1998, 1999; MacDonald 1994; Dolan & Wodak 1999 Canada4,28511 Correc. Services Canada 1995 Canada105 (F)19 Di Censo, Dias, Gahagan 2003 Canada>1, Small et al England Edwards et al 1999 Europe*87113 Rotily et al 2001 EU & Nor EMCDD 2005 Greece Koulierakis et al 1999 Mauritius RSA Mauritius 2005 Russia1, Frost, Tscherkov 2002 Russia27713 Dolan et al 2004 Thailand Thaisri et al 2003 USA47215% Clarke et al 2001

Distribution machine: Hindelbank, CH Hand-to-hand exchange: Geneva, CH Needle and syringe exchange

Hand-to hand distribution Injection/prevention kit Spain Injection/prevention kit Switzerland

Prevents HIV infection No negative consequences No increase of drug use or drug injection Needles not used as weapons Facilitate referral of drug users to drug dependence treatment programs Proof of efficacy of needle exchange programs in prison WHO 2007 Jürgens, Lancet Inf Dis 2009

Global availability of needle and syringe programs (NSP) in the community and in prisons Harm Reduction International, The global state of harm reduction 2012

Needle exchange at the prison of Champ-Dollon, CH Start 1996: principle of equivalence → cantonal law in 2000 Pragmatic approach (consider the fact that drugs enter each prison in the world) Support by prison authorities At entry: Information concerning the possibility to obtain injection material for free and in a confidential way Information at the medical unit (=confidentiality), then distribution at the cell door (=security)

Syringe exchange at the prison of Champ-Dollon,

Problems and solutions Initial mistrust, fear of the syringe as potential weapon (detention officers) – Frequent exchanges between stake holders improved acceptance of all – Improvement of the culture of dialogue – Prison direction implicated in public health strategies Proportion of needles returned to the health team – Trust building – Ask the detainees (=experts)

Problems and solutions II Acceptance by the detainees? Fear of denunciation? – Importance of confidentiality – Separation of the hierarchies (independence medical / prison staff) helps – Participative approach in the improvement process – Initiate other ways of syringe distribution Syringe sharing still exists – Evaluate situation properly – Other distribution methods (automates)?

Conclusions Addiction and associated health problems is of major concern in detention Effective harm reduction strategies exist OST, condom distribution and Needle exchange in prison are – Necessary and FEASABLE – Effective and low cost measures – Should be implemented in every prison – worldwide! Opportunity to improve the health of the entire community (improve public health!)